nach oben

Zeitschrift für Rheumatologie

Erschienen in:

27.05.2021 | Chronisch-entzündliche Darmerkrankungen | CME

Update: enteropathische Spondyloarthritis

verfasst von: Prof. Dr. med. Elisabeth Märker-Hermann

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Spondyloarthritiden (SpA) gehören zu den häufigsten extraintestinalen Manifestationen der chronisch entzündlichen Darmerkrankungen (CED). Auch bestimmte arthritogene Enterobakterien können als Folgeerkrankung der Gastroenteritis eine reaktive enteropathische SpA auslösen. Die Erforschung der „Darm-Synovium-Achse“ unter genetischen, immunologischen, klinischen und therapeutischen Gesichtspunkten hat die enteropathische SpA zu einer Modellerkrankung der SpAs gemacht. Ähnliches gilt für die Erforschung der CED, da die subklinischen Darmentzündungen bei Patienten mit SpA dazu beigetragen haben, die Mukosa-assoziierten frühen Immunphänomene des Morbus Crohn (CD) besser zu verstehen. Dieser Beitrag stellt neben den pathognomonischen klinischen Bildern, der Diagnostik und Differenzialdiagnostik die aktuellen pathogenetischen Modelle der enteropathischen SpAs vor. Aus dem Wissen um pathogenetische Zusammenhänge ergeben sich konkrete Empfehlungen zur Therapie, wobei individuell nach der zugrunde liegenden Darmerkrankung, nach der entzündlichen intestinalen oder rheumatischen Aktivität und nach dem rheumatologischen Befallsmuster unterschieden wird.

Rudwaleit M, Baeten D (2006) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 20:451PubMedCrossRef

Shivashankar R, Loftus EV Jr, Tremaine WJ, Bongartz T, Harmsen WS, Zinsmeister AR (2012) Matteson EL Incidence of spondyloarthropathy in patients with Crohn’s disease: a population-based study. J Rheumatol 39:2148–2152PubMedPubMedCentralCrossRef

Shivashankar R, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Matteson EL (2013) Incidence of Spondyloarthropathy in patients with ulcerative colitis: a population-based study. J Rheumatol 40:1153–1157PubMedCrossRef

Vavricka SR, Brun L, Ballabeni P et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106:110–119PubMedCrossRef

Karreman MC, Luime JJ, Hazes JM, Weel AE (2017) The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 11:631–642PubMed

Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP (2000) Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 118:274–278PubMedCrossRef

Peeters H, Vander Cruyssen B, Laukens D et al (2004) Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn’s disease. Ann Rheum Dis 63:1131–1134PubMedPubMedCentralCrossRef

Zeitz J, Vavricka SR (2013) Therapie der extraintestinalen CED-Manifestationen : Eine schwierige Herausforderung. Gastroenterologe 8:217–225CrossRef

Travis S (1997) Sweet’s syndrome: an unusual cutaneous feature of Crohn’s disease or ulcerative colitis. The south west gastroenterology group. Eur J Gastroenterol Hepatol 9:15–720CrossRef

10.

Märker-Hermann E (2020) Reaktive Arthritis – eine vergessene Erkrankung? Dtsch Med Wochenschr 145:1786–1790PubMedCrossRef

11.

Ajene AN, Fischer Walker CL, Black RE (2013) Enteric pathogens and reactive arthritis: a systematic review of campylobacter, salmonella and shigella-associated reactive arthritis. J Health Popul Nutr 31:299PubMedPubMedCentralCrossRef

12.

Vasala M, Hallanvuo S, Ruuska P et al (2014) High frequency of reactive arthritis in adults after Yersinia pseudotuberculosis O:1 outbreak caused by contaminated grated carrots. Ann Rheum Dis 73:1793–1796PubMedCrossRef

13.

Tuompo R, Lääveri T, Hannu T et al (2020) Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic escherichia coli (DEC). Ann Rheum Dis 79:605–611PubMedCrossRef

14.

Mielants H, Veys EM, Cuvelier C et al (1995) The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 22:2273–2278PubMed

15.

Mielants H, Veys EM, Cuvelier C, De Vos M (1996) Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 10:147–164PubMedCrossRef

16.

Van Praet L, Van den Bosch FE, Jacques P et al (2013) Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 72:414–417PubMedCrossRef

17.

Klingberg E, Strid H, Ståhl A et al (2017) A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 19(1):21PubMedPubMedCentralCrossRef

18.

Rudwaleit M, van der Heijde D, Landewe R et al (2011) The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31PubMedCrossRef

19.

Rudwaleit M, van der Heijde D, Landewe R et al (2009) The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783PubMedCrossRef

20.

Chan J, Sari I, Salonen D, Silverberg MS et al (2018) Prevalence of sacroiliitis in inflammatory bowel disease using a standardized CT scoring system. Arthritis Care Res (Hoboken) 70:807–810CrossRef

21.

Kiltz U, Braun J, DGRh et al (2019) Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019. Z Rheumatol 78:3–64PubMedCrossRef

22.

Leclerc-Jacob S, Lux G, Rat AC et al (2014) The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther 39:957–962PubMedCrossRef

23.

de Miguel E, Cobo T, Muñoz-Fernández S et al (2009) Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 68:169–174PubMedCrossRef

24.

Silverberg MS, Mirea L, Bull SB et al (2003) A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 9:1–9PubMedCrossRef

25.

Ossum AM, Palm Ø, Lunder AK et al (2018) Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study. J Crohns Colitis 12:96–104PubMedCrossRef

26.

De Vos M, Hindryckx P, Laukens D (2011) Novel development in extraintestinal manifestations and spondylarthropathy. Best Pract Res Clin Gastroenterol 25(1):S19–S26PubMedCrossRef

27.

van der Paardt M, Crusius JBA, de Koning MHMT et al (2003) CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun 4:77–78PubMedCrossRef

28.

D’Amato M, Sorrentino R, Pettersson S (2014) The Crohn’s associated NOD2 3020InsC frameshift mutation does not confer susceptibility to ankylosing spondylitis. J Rheumatol 41:187

29.

Laukens D, Peeters H, Marichal D et al (2005) CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn’s disease. Ann Rheum Dis 64:930–935PubMedCrossRef

30.

Danoy P, Pryce K, Hadler J et al (2010) Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn’s disease. PLoS Genet 6:e1001195PubMedPubMedCentralCrossRef

31.

Laukens D, Georges M, Libioulle C et al (2010) Evidence for significant overlap between common risk variants for Crohn’s disease and ankylosing spondylitis. PLoS One 5:e13795PubMedPubMedCentralCrossRef

32.

Pointon JJ, Harvey D, Karaderi T et al (2010) Elucidating the chromosome 9 association with AS; CARD9 is a candidate gene. Genes Immun 11:490–496PubMedPubMedCentralCrossRef

33.

Duerr RH, Taylor KD, Brant SR et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461–1463PubMedPubMedCentralCrossRef

34.

The Australo-Anglo-American Spondyloarthritis Consortium (TASC) (2010) Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42:123–127CrossRef

35.

Van Deventer SJ (1997) Tumour necrosis factor and crohn’s disease. Gut 40:443–448PubMedPubMedCentralCrossRef

36.

Leppkes M, Roulis M, Neurath MF et al (2014) Pleiotropic functions of TNF‑α in the regulation of the intestinal epithelial response to inflammation. Int Immunol 26:509–515PubMedCrossRef

37.

Mei Y, Pan F, Gao J et al (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30:269–273PubMedCrossRef

38.

Appel H, Maier R, Wu P et al (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13:R95PubMedPubMedCentralCrossRef

39.

Ciccia F, Bombardieri M, Principato A et al (2009) Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 60:955–965PubMedCrossRef

40.

Sherlock JP, Joyce-Shaikh B, Turner SP et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076PubMedCrossRef

41.

Benham H, Rehaume LM, Hasnain SZ et al (2014) Interleukin-23 mediates the intestinal response to microbial β‑1,3‑glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol 66:1755–1767PubMedCrossRef

42.

Taurog JD, Richardson JA, Croft JT et al (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364PubMedCrossRef

43.

Breban M, Tap J, Leboime A et al (2017) Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis 76:1614–1622PubMedCrossRef

44.

Tito RY, Cypers H, Joossens M et al (2017) Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol 69:114–121PubMedCrossRef

45.

Gracey E, Qaiyum Z, Almaghlouth I et al (2016) IL‑7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis 75:2124–2132PubMedCrossRef

46.

Qaiyum Z, Gracey E, Yao Y, Inman RD (2019) Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis. Ann Rheum Dis 78:1566PubMedCrossRef

47.

May E, Märker-Hermann E, Wittig BM et al (2000) Identical T‑cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 119:1745–1755PubMedCrossRef

48.

Severs M, van Erp SJ, van der Valk ME, Dutch Initiative on Crohn and Colitis et al (2016) Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10:455–461PubMedCrossRef

49.

Preiß JC, Bokemeyer B, Buhr HJ et al (2014) Aktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014. AWMF-Registrierungsnummer: 021-004. Z Gastroenterol 52:1431–1484PubMedCrossRef

50.

Kucharzik T, Dignass AU, Atreya R et al (2020) Aktualisierte S3-Leitlinie Colitis ulcerosa—Living Guideline August 2020—AWMF-Registriernummer: 021-009. Z Gastroenterol 58:e241–e345PubMedCrossRef

51.

Tadbiri S, Peyrin-Biroulet L, Serrero M, Getaid Observ-IBD study group et al (2018) Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the Observ-IBD cohort. Aliment Pharmacol Ther 47:485–493PubMedCrossRef

52.

Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veterans affairs cooperative study. Arthritis Rheum 42:2325–2329PubMedCrossRef

53.

Van den Bosch F, Kruithof E, De Vos M et al (2000) Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356:1821–1822PubMedCrossRef

54.

Generini S, Giacomelli R, Fedi R et al (2004) Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 63:1664–1669PubMedPubMedCentralCrossRef

55.

Luchetti MM, Benfaremo D, Ciccia F et al (2017) Adalimumab efficacy in enteropathic spondyloarthritis: a 12-mo observational multidisciplinary study. World J Gastroenterol 23:7139–7149PubMedPubMedCentralCrossRef

56.

Sandborn WJ, Hanauer SB, Katz S et al (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088–1094PubMedCrossRef

57.

Marzo-Ortega H, McGonagle D, O’Connor P et al (2003) Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 62:74–76PubMedPubMedCentralCrossRef

58.

Sandborn WJ, Gasink C, Gao LL et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 367:1519–1528PubMedCrossRef

59.

Sands BE, Sandborn WJ, Panaccione R et al (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201–1214PubMedCrossRef

60.

Deodhar A, Gensler LS, Sieper J et al (2019) Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 71:258–270PubMedCrossRef

61.

Song X, Dai D, He X, Zhu S, Yao Y, Gao H, Wang J, Qu F, Qiu J, Wang H et al (2015) Growth factor FGF2 cooperates with Interleukin-17 to repair intestinal epithelial damage. Immunity 43:488–501PubMedCrossRef

62.

Burisch J, Eigner W, Schreiber S et al (2020) Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis. PLoS ONE 15(5):e233781PubMedPubMedCentralCrossRef

Titel: Update: enteropathische Spondyloarthritis
verfasst von: Prof. Dr. med. Elisabeth Märker-Hermann
Publikationsdatum: 27.05.2021
Verlag: Springer Medizin
Schlagwörter: Chronisch-entzündliche Darmerkrankungen
Colitis ulcerosa
Morbus Crohn
Arthritis
Spondyloarthritiden
Spondylitis ankylosans
Reaktive Arthritis
Erythema nodosum
Erythema nodosum
Erythema nodosum
Uveitis
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 6/2021
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-021-01014-2

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Achtzig Jahre Rheumatologie – Meilensteine in Diagnose, Therapie und Forschung

Mitteilungen des BDRh

Erratum to: Diagnostic value of the CD 15 focus score in two-stage revision arthroplasty of periprosthetic joint infections. High specificity in diagnosing infect eradication

Mitteilungen der DGRh - Veranstaltungen der Rheumaakademie

Association of urate deposition shown by ultrasound and frequent gout attacks

Post-COVID‑19-Arthritis. Manifestation unter dem klinischen Bild einer reaktiven Arthritis

Magen-Darm-Erkrankungen in der Hausarztpraxis